Part 1: MASLD: Overview & Screening Recommendations

1. Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) is the leading cause of liver transplantation.

a) True
b) False

2. While Non-alcoholic Fatty Liver Disease (NAFLD) and MASLD generally refer to the same condition, a key distinction is that a NAFLD diagnosis excludes other liver diseases, whereas MASLD is based on affirmative criteria.

a) True
b) False

3. Cardiovascular disease is reported to be the most common cause of mortality in patients with MASLD.

a) True
b) False

4. MASLD is defined as the presence of hepatic steatosis in conjunction with what cardiometabolic risk factor(s):

a) Visceral obesity
b) Pre-diabetes/diabetes
c) Hypertension
d) Atherogenic dyslipidemia
e) All of the above

5. Cirrhosis of the liver is a condition where healthy liver tissue is replaced by scar tissue, hindering the liver’s ability to function properly, and can lead to liver failure.

a) True
b) False

6. Increased insulin resistance associated with MASLD causes which of the following:

a) Oxidative stress
b) Plaque formation
c) Harmful cytokines and chemokines
d) Inflammation
e) All of the above

7. Hepatocellular carcinoma (HCC) is now the fifth most common cause of cancer worldwide and a major cause of cancer death with only a 18% five-year survival rate.

a) True
b) False

8. The following condition(s) can affect the FibroScan results:

a) Ascites
b) Biliary obstruction
c) Hepatic tumors
d) Hepatic inflammation
e) All of the above

9. The American Diabetes Association 2025 Standards of Care recommends screening adults with type 2 diabetes or with prediabetes for their risk of having or developing cirrhosis related to metabolic dysfunction–associated steatohepatitis (MASH) using a calculated fibrosis-4 index (FIB-4), even if they have normal liver enzymes.

a) True
b) False